In this episode of the Tapped In podcast, Bud and Mike discuss the recent news that the DEA is planning to reschedule cannabis into a schedule three narcotic. They explore the implications of this change, including the potential for increased research and development opportunities, the impact on different states' regulations, and the potential involvement of beverage companies like Coke and Pepsi. They also discuss the rise of Delta 9 variant cannabis beverages and the challenges and opportunities for beverage distributors in this new market. The conversation touches on topics such as drug testing, taxation, and the potential for celebrity endorsements in the THC space.

Takeaways

Chapters

02:15 The DEA's Plan to Reschedule Cannabis

03:15 Implications of the Rescheduling

05:09 Delta 9 Variant Cannabis Beverages

07:02 Impact on the Alcohol Industry

08:00 Potential Involvement of Coke and Pepsi

09:25 The Market for THC-Infused Beverages

10:18 Understanding Delta 9 Variant Products

11:18 The Presence of Delta 9 in On-Premise Locations

17:29 Challenges of Drug Testing in the THC Space

19:23 Updating Drug Testing Policies

20:42 Regulation and Taxation in the Cannabis Industry

23:40 Predictions for the Future of the THC Space

26:33 Conclusion and Reflections